Can a drug make radiation work better against aggressive brain tumors?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have pathologically confirmed (histology or cytology), resectable or non resectable, glioblastoma multiforme with a size \< 5 cm on MRI if non resectable * Patients must be at least 7 days but no more than 2 months since surgery or biopsy. * Patients must have an ECOG Performance Status ≤ 2. * Patients must be aged 18 * Patient has signed the informed consent form Exclusion Criteria: * Patients with unresectable glioblastoma with a size \>5 cm on MRI * Patients with clinically apparent leptomeningeal metastases * Patients with uncontrolled seizures despite standard anticonvulsant therapy * Any prior systemic treatment (chemotherapy, immunotherapy, hormonal therapy) for glioblastoma multiforme * Significantly abnormal haematological status as judged by: Absolute neutrophil count (ANC) \< 1500/mm3 (1.5\*109/l) Platelet count \<100,000/mm3 (100\*109/l) * Serum bilirubin \>2 mg/dl (\>34 mmol/l) or Transaminase \>2.5x the upper limit of institutional normal or Creatinine \>1.5 mg/dl (\>132 mmol/l) * Inability to co-operate with the treatment protocol * Patients who cannot undergo imaging evaluations * Participation in an investigational drug trial in the 30 days prior to selection * Pregnant or nursing mothers. (Female patients of childbearing potential must use adequate contraception.) * Any malignancy within the past five years. Exceptions are: superficial basal cell carcinoma or non-metastatic squamous cell cancer of the skin, cervix cancer (cervical intra-epithelial neoplasia -CIN or FIGO stage 1) or prostate intra-epithelial neoplasia (PIN), biochemical relapse free for at least 3 years. * Any prior systemic chemotherapy in the past five years for any malignancy in the medical history * Any concurrent disease that in the opinion of the investigator would constitute a hazard for participating in this study * Known sensitivity to imidazole derivatives * Patients under law protection * Medical history of phlebitis or pulmonary embolism, thrombocytosis, myocardiopathy, or other relevant cardiac pathology (auricular flutter, auricular fibrillation) * Medical history of immuno-allergic pneumopathy